USSN 10/813,870

CT-2773 NP

## Remarks

Restriction requirement. The examiner required an inter-claim election between group I (drawn to chemical compounds and compositions) and group II (drawn to methods of treatment). In response, the applicants provisionally elect group I with traverse.

Because the method of treatment claims relate directly to the scope of the compound claims and will be rejoined with subsequently allowed compound claims under MPEP 821.04 (as noted by the examiner), the applicants traverse the requirement as creating more of a burden for the examiner than examining the claims together.

In response to the requirement to elect a species, the applicants provisionally elect (3R)-N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pymolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (example 18). Claims 1-5 and 8-11 read on this compound.

The examiner made no regulrement for an intra-claim restriction.

The applicants believe they have complied with all of the examiners requirements and respectfully request favorably reconsideration of the restriction requirement.

Sincerely,

Date:

Bristol-Myers Squibb Company

Patent Department P.O. Box 4000

Princeton, NJ 08543-4000

James Epperson Agent for Applicants Reg. No. 52,867

Phone: (203) 677-6974